Cantor Initiates Heron Therapeutics With Buy Rating, $41 Price Target By: Benzinga via Benzinga May 03, 2016 at 09:00 AM EDT Cantor Fitzgerald’s Chiara Russo mentioned that with Heron Therapeutics Inc (NASDAQ: HRTX)'s lead product, Sustol, coming up for ... Read More >> Related Stocks: Heron Therapeutics